235
Participants
Start Date
December 12, 2011
Primary Completion Date
June 25, 2012
Study Completion Date
June 25, 2012
PF-05089771
A single dose of PF-05089771 1600 mg oral solution administered once to the subject on Day 1 postoperatively
Placebo
Placebo tablets for ibuprofen: 2 X 200 mg placebo tablets administered orally once to the subject on Day 1 postoperatively
PF-05089771
A single dose of PF-05089771 450 mg oral solution administered once to the subject on Day 1 postoperatively
Placebo
Placebo tablets for ibuprofen: 2 X 200 mg placebo tablets administered orally once to the subject on Day 1 postoperatively
PF-05089771
A single dose of PF-05089771 150 mg oral solution administered once to the subject on Day 1 postoperatively
Placebo
Placebo tablets for ibuprofen: 2 X 200 mg placebo tablets administered orally once to the subject on Day 1 postoperatively
Ibuprofen
2 X 200 mg tablets of ibuprofen administered orally once to the subject on Day 1 postoperatively
Placebo
Placebo solution for PF-05089771: A single dose of Placebo solution administered once to the subject on Day 1 postoperatively
Placebo
Placebo solution for PF-05089771:A single dose of Placebo solution administered once to the subject on Day 1 postoperatively
Placebo
Placebo tablets for Ibuprofen: 2 X 200 mg placebo tablets administered orally once to the subject on Day 1 postoperatively
Central Texas Oral Surgery Associates, Austin
Premier Research Group Limited, Austin
PPD Development, LP, Austin
Lead Sponsor
Pfizer
INDUSTRY